US FDA: Pfizer has given adequate information on vaccine quality

The US FDA briefs ahead of the panel decision on 10 December

This is basically a “heads up” by the US FDA as to what to expect in the next two days when the advisory panel announces their decision. Rightfully, this should already be baked into the market but the headline could still cause the algos to get a bit jumpy for a moment.